Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands

Central and peripheral exercise-related factors independently associated with presence of HFpEF

Literature - Mar. 21, 2019 - Wolsk E et al. - JACC Heart Failure 2019

Pulmonary capillary wedge pressure (PCWP), BMI and stroke volume were independently associated with the presence of HFpEF, compared with healthy subjects exercising at the same workloads.

Echocardiographic predictors of clinical outcomes in patients with HF and severe secondary mitral regurgitation

News - Mar. 21, 2019

ACC 2019 In an echocardiography substudy of the COAPT trial, predictors of poor outcomes were studied in HF patients with severe secondary mitral regurgitation.

Early in-hospital initiation of ARNI after ADHF improves outcomes in HFrEF

News - Mar. 21, 2019

ACC 2019 An open-label extension study of the PIONEER-HF trail showed that in-hospital initiation of sacubitril/valsartan (S/V) improved clinical outcomes after ADHF among HFrEF patients, compared to in-hospital initiation of enalapril followed by S/V.

Pulmonary artery pressure-guided therapy reduced HHF and was safe in HF patients

News - Mar. 19, 2019

ACC 2019 Post-approval analyses of the CardioMEMS PAS trial showed that adapting therapy based on pulmonary artery pressure is effective in reducing hospitalizations for HF and safe in patients with NYHA class III HF.

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD
Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

ACC 2019 Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

SGLT2 inhibitor treatment is beneficial in T2DM patients with a broad range of ejection fractions

News - Mar. 19, 2019

ACC 2019 An analysis of DECLARE-TIMI 58 showed that dapagliflozin was associated with reduced hospitalization for HF and CV death across a range of EF. Benefit seems largest in HFrEF.

Prognostic value of IL-1β and a potential role of inflammation signaling in ADHF

Literature - Mar. 12, 2019 - Pascual-Figal DA et al. - JACC 2019
This observational study showed prognostic value of IL-1β for acutely decompensated HF (ADHF) in those with high sST2 (IL-1 receptor) levels, and a meaningful correlation between IL-1β and sST2.

This observational study showed prognostic value of IL-1β for acutely decompensated HF (ADHF) in those with high sST2 (IL-1 receptor) levels, and a meaningful correlation between IL-1β and sST2.

Clinical characteristics, treatment patterns and outcomes in real-world HFrEF patients with worsening HF

Literature - Mar. 11, 2019 - Butler J et al. - JACC 2019
In real-world setting, HFrEF patients who developed worsening HF had high comorbidity burden and poor outcomes, with low observed medication use and suboptimal dosing before and after chronic worsening HF events.

In real-world setting, HFrEF patients who developed worsening HF had high comorbidity burden and poor outcomes, with low observed medication use and suboptimal dosing before and after chronic worsening HF events.

Striking underuse of therapies for HFrEF not explained by low blood pressure

Literature - Feb. 19, 2019 - Peri-Okonny PA et al., - JACC : Heart Failure 2019

The contemporary CHAMP-HF registry of HFrEF patients revealed that <10% of patients eligible for ACEi/ARB/ARNI and BB therapy received target doses, also when SBP was >110 mmHg.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Treatment with ARNI improves mitral regurgitation in HF patients

Literature - Feb. 4, 2019 - Kang D-H et al. - Circulation 2018

The combination of sacubitril/valsartan reduced mitral regurgitation, measured by change in effective regurgitant orifice area, to a greater extent than valsartan alone in HF patients in the PRIME study.

Higher absolute risk for adverse events with MRA in HFpEF patients in lower eGFR categories

Literature - Jan. 28, 2019 - Beldhuis IE et al. - JACC: Heart Failure 2019

A post-hoc analysis of the TOPCAT trial showed increased absolute risk for study drug discontinuation due to AEs with spironolactone in HFpEF patients with eGFR ≤60 mL/min/1.73m², compared to higher eGFR categories.